

Equity Research
EuropeQuick Comment
Insurance

Swiss Re

STOCK RATING	OVERWEIGHT
Price (Dec 8, 2003)	SFr 82
Price Target	SFr 98

Stock ratings are relative to the analyst's industry (or industry team's) coverage universe.

Quick Comment

December 8, 2003

Innovative Mortality-Based Security

Swiss Re has launched an innovative fixed income security, the first of its kind, related to “extreme mortality risk”. While relatively modest in size, the details of the structure provide us with an insight into Swiss Re’s thinking on capital requirements within life reinsurance — and we think demonstrate the company’s ability to benefit from capital arbitrage within this business.

A Swiss Re-sponsored Special Purpose Vehicle (SPV) called Vita Capital has raised \$400mn from bond investors who will be remunerated by way of a quarterly coupon set at US LIBOR plus 135bp. The term of the bond is four years and the principal is at risk should mortality of the general population based on a weighted average of the US, UK, France, Italy and Switzerland exceed 130% of the actual 2002 level. The principal would be exhausted should the same measure exceed 150% of the 2002 level. In actual fact, mortality has been improving consistently over recent decades and a situation even breaching the low end of this range 130-150% of 2002 should be considered extremely unlikely — possibly on the scale of the 1918 influenza epidemic - and necessarily of global (or at least US and European) proportions.

Why has Swiss Re done this?

Understanding the true economic capital requirements of life reinsurance business is not straightforward — there is little guidance on the subject from rating agencies or regulators — and we think it is the corporates themselves — especially the global market leader Swiss Re (market share ~25%) - that probably have the best insight and therefore potential ability to benefit from arbitrage opportunities. *Swiss Re must be taking a view that the cost of capital that is relieved via this transaction exceeds the effective net cost of servicing the bond.*

If we assume that Swiss Re invests the proceeds of the bond in a risk-free manner then we might regard the annual cost to Swiss Re as being 135bp of \$400mn or \$5.4mn. Assuming a cost of capital of 9%, then we might suggest that at least **\$60mn (5.4/0.09) of capital is relieved** as a result of the transaction, say SFr 100mn.

Looking at the embedded value disclosure, we note adjusted net shareholders worth of SFr 7.7bn at end 2002. Thus this is not especially material — a relief of only 1.3% of the existing capital base.

Looked at another way, we know Swiss Re had claims of SFr 10,084mn in its life business in 2002 — equal to around 32bp of the sum at risk of ~\$2trillion. Observed mortality in the range 130-150% of this base would give claims of SFr 13.1bn to SFr 15.1bn — a range of SFr 2,017mn or \$1,260mn. Thus protection for around one-third of this range is afforded by the new security — opening the possibility for future tranches of similar securities — at this range (130-150%) or other ranges of observed mortality at the adverse end of the tail. We understand that appetite for this security from investors was strong.

We might additionally infer that Swiss Re’s economic capital model says that there is a probability of at least **~4%** (1,260/400 x 1.3%) that the bottom end of this range is breached in any year (i.e. this represents a one in twenty-five year event). Intuitively this perhaps suggests that the capital model is relatively conservative.

Morgan Stanley does and seeks to do business with companies covered in its research reports. Investors should consider this report as only a single factor in making their investment decision.


Please see analyst certification and other important disclosures starting on page 3.

Swiss Re's life reinsurance business accounted for 43% of group revenues in 2002, up from 38% in 2001. The return on operating revenues was 9.1% in 2002, in line with management's target of 9%, based on an operating result of SFr 1,344m and operating revenues of SFr 14,751m.

We rate Swiss Re Overweight with a price target of SFr 98, upside potential of 20%.

Exhibit 1

Mortality-Based Security



Source: Company data, Morgan Stanley Research

Valuation rationale/risk discussion: We value the non-life reinsurance businesses at 11x earnings, assuming a combined ratio over the cycle of 102% and a 'normalised' investment return of 5%. We value the resulting normalised earnings on a P/E multiple reflecting the longer term excess returns generated through these assumptions. We value the life business at a 7x multiple of new business. Non-life/reinsurance is a business of risk transfer, and as such, stocks with high exposure to non-life and reinsurance may be adversely affected by large and unexpected losses, especially from natural catastrophes, or positively affected in years of unusually low severity of major claims. Further adverse development of reserves, particularly relating to accident years 1997-2000, would also have negative impact upon the stock concerned. In addition, significant movements in equity and bond markets can reflect materially on the results and balance sheets of the stocks.

Industry view: In-line. Fundamentals have improved helped by markets and corporate actions.

Contact details:

Rob Procter +44 (0)20 7513 6477

rob.procter@morganstanley.com

Chris.Hartwell +44 (0)20 7513 4385

chris.hartwell@morganstanley.com

Please see analyst certification and other important disclosures starting on page 3.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Rob Procter.

Important US Regulatory Disclosures on Subject Companies

The information and opinions in this report were prepared by Morgan Stanley & Co. International Limited and its affiliates (collectively, "Morgan Stanley").

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Swiss Re.

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Swiss Re.

The research analysts, strategists, or research associates principally responsible for the preparation of this research report have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues.

Morgan Stanley & Co. Incorporated makes a market in the securities of Swiss Re.

Global Stock Ratings Distribution

(as of November 30, 2003)

Stock Rating Category	Coverage Universe		Investment Banking Clients (IBC)		
	Count	% of Total	Count	% of Total IBC	% of Rating Category
Overweight	578	31%	237	39%	41%
Equal-weight	861	47%	283	46%	33%
Underweight	404	22%	93	15%	23%
Total	1,843		613		

Data include common stock and ADRs currently assigned ratings. For disclosure purposes (in accordance with NASD and NYSE requirements), we note that Overweight, our most positive stock rating, most closely corresponds to a buy recommendation; Equal-weight and Underweight most closely correspond to neutral and sell recommendations, respectively. However, Overweight, Equal-weight, and Underweight are not the equivalent of buy, neutral, and sell but represent recommended relative weightings (see definitions below). An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations. Investment Banking Clients are companies from whom Morgan Stanley or an affiliate received investment banking compensation in the last 12 months.

Analyst Stock Ratings

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

More volatile (V). We estimate that this stock has more than a 25% chance of a price move (up or down) of more than 25% in a month, based on a quantitative assessment of historical data, or in the analyst's view, it is likely to become materially more volatile over the next 1-12 months compared with the past three years. Stocks with less than one year of trading history are automatically rated as more volatile (unless otherwise noted). We note that securities that we do not currently consider "more volatile" can still perform in that manner.

Unless otherwise specified, the time frame for price targets included in this report is 12 to 18 months. Ratings prior to March 18, 2002: SB=Strong Buy; OP=Outperform; N=Neutral; UP=Underperform. For definitions, please go to www.morganstanley.com/companycharts.

Analyst Industry Views

Attractive (A). The analyst expects the performance of his or her industry coverage universe to be attractive vs. the relevant broad market benchmark over the next 12-18 months.


In-Line (I). The analyst expects the performance of his or her industry coverage universe to be in line with the relevant broad market benchmark over the next 12-18 months.

Cautious (C). The analyst views the performance of his or her industry coverage universe with caution vs. the relevant broad market benchmark over the next 12-18 months.

Stock price charts and rating histories for companies discussed in this report are also available at www.morganstanley.com/companycharts. You may also request this information by writing to Morgan Stanley at 1585 Broadway, 14th Floor (Attention: Research Disclosures), New York, NY, 10036 USA.

Stock Price, Price Target and Rating History (See Rating Definitions)

Swiss Re (RUKN.WX) - As of 12/8/03 in CHF
Industry : Insurance



Volatility (Introduced 3/9/01. Shading indicates "more volatile" (V) ratings.)



Stock Rating History: 10/20/98 : OP; 3/23/01 : SB; 7/30/01 : NAV; 7/31/01 : SB; 3/1/02 : OP; 3/18/02 : O/I;
9/2/02 : O/C; 9/8/03 : O/I
Price Target History: 11/24/00 : 4500; 7/30/01 : NA; 8/1/01 : 225; 3/1/02 : 200; 4/11/02 : 193; 5/31/02 : 190;
7/1/02 : 182; 8/2/02 : 143; 8/30/02 : 139; 9/23/02 : 122; 11/1/02 : 130; 1/10/03 : 137; 1/31/03 : 129;
2/27/03 : 102; 3/31/03 : 92; 4/3/03 : 93; 4/29/03 : 103; 7/3/03 : 102; 7/10/03 : 98

Source: Morgan Stanley Research Date Format : MM/DD/YY Price Target -- No Price Target Assigned (NA)
Stock Price (Not Covered by Current Analyst) — Stock Price (Covered by Current Analyst) ■
Stock Ratings abbreviated as below (Effective 3/18/02, ratings appear as Stock Ratings/Industry View) ♦
Stock Ratings as of 3/18/02: Overweight (O) Equal-weight (E) Underweight (U) More Volatile (V) No Rating Available (NAV)
Stock Ratings prior to 3/18/02: Strong Buy (SB) Outperform (OP) Neutral (N) Underperform (UP) No Rating Available (NAV)
Industry View: Attractive (A) In-line (I) Cautious (C) No Rating (NR)

Other Important Disclosures

For a discussion, if applicable, of the valuation methods used to determine the price targets included in this summary and the risks related to achieving these targets, please refer to the latest relevant published research on these stocks. Research is available through your sales representative or on Client Link at www.morganstanley.com and other electronic systems.

This report does not provide individually tailored investment advice. It has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. The securities discussed in this report may not be suitable for all investors. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives.

This report is not an offer to buy or sell any security or to participate in any trading strategy. In addition to any holdings disclosed in the section entitled "Important US Regulatory Disclosures on Subject Companies", Morgan Stanley and/or its employees not involved in the preparation of this report may have investments in securities or derivatives of securities of companies mentioned in this report, and may trade them in ways different from those discussed in this report. Derivatives may be issued by Morgan Stanley or associated persons.

Morgan Stanley is involved in many businesses that may relate to companies mentioned in this report. These businesses include specialized trading, risk arbitrage and other proprietary trading, fund management, investment services and investment banking.

Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in this report change apart from when we intend to discontinue research coverage of a subject company.

Reports prepared by Morgan Stanley research personnel are based on public information. Facts and views presented in this report have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

The value of and income from your investments may vary because of changes in interest rates or foreign exchange rates, securities prices or market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in your securities transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized.

This publication is disseminated in Japan by Morgan Stanley Japan Limited; in Hong Kong by Morgan Stanley Dean Witter Asia Limited; in Singapore by Morgan Stanley Dean Witter Asia (Singapore) Pte., regulated by the Monetary Authority of Singapore; in Australia by Morgan Stanley Dean Witter Australia Limited A.B.N. 67 003 734 576, a licensed dealer, which accepts responsibility for its contents; in certain provinces of Canada by Morgan Stanley Canada Limited, which has approved of, and has agreed to take responsibility for, the contents of this publication in Canada; in Spain by Morgan Stanley, S.V., S.A., a Morgan Stanley group company, which is supervised by the Spanish Securities Markets Commission (CNMV) and states that this document has been written and distributed in accordance with the rules of conduct applicable to financial research as established under Spanish regulations; in the United States by Morgan Stanley & Co. Incorporated and Morgan Stanley DW Inc., which accept responsibility for its contents. Private U.K. investors should obtain the advice of their Morgan Stanley & Co. International Limited representative about the investments concerned. In Australia, this report, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act.

The trademarks and service marks contained herein are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property of MSCI and S&P.

This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Additional information on recommended securities is available on request.

The Americas

1585 Broadway
New York, NY 10036-8293
United States
Tel: +1 (1)212 761 4000

Europe

25 Cabot Square, Canary Wharf
London E14 4QA
United Kingdom
Tel: +44 (0)20 7513 8000

Japan

20-3, Ebisu 4-chome
Shibuya-ku,
Tokyo 150-6008, Japan
Tel: +81 (0)3 5424 5000

Asia/Pacific

Three Exchange Square
Central
Hong Kong
Tel: +852 2848 5200